Cytokinetics (CYTK) Debt to Equity (2016 - 2025)
Cytokinetics (CYTK) has disclosed Debt to Equity for 14 consecutive years, with -$0.44 as the latest value for Q4 2025.
- On a quarterly basis, Debt to Equity changed N/A to -$0.44 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.44, a N/A change, with the full-year FY2025 number at -$0.44, changed N/A from a year prior.
- Debt to Equity was -$0.44 for Q4 2025 at Cytokinetics, down from -$0.34 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $2.84 in Q2 2021 to a low of -$7.59 in Q3 2024.
- A 5-year average of -$0.46 and a median of -$0.17 in 2024 define the central range for Debt to Equity.
- Biggest YoY gain for Debt to Equity was 612.43% in 2024; the steepest drop was 5366.65% in 2024.
- Cytokinetics' Debt to Equity stood at $0.19 in 2021, then crashed by 409.04% to -$0.6 in 2022, then skyrocketed by 74.82% to -$0.15 in 2023, then crashed by 4919.04% to -$7.59 in 2024, then soared by 94.25% to -$0.44 in 2025.
- Per Business Quant, the three most recent readings for CYTK's Debt to Equity are -$0.44 (Q4 2025), -$0.34 (Q3 2025), and -$0.48 (Q2 2025).